Intravitreal Injections and Diabetic Macular Edema: Actual and New Therapeutic Options

ISSN: 1875-6417 (Online)
ISSN: 1573-3998 (Print)


Volume 10, 6 Issues, 2014


Download PDF Flyer




Current Diabetes Reviews

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Norman E. Cameron
University of Aberdeen
Aberdeen, Scotland
UK


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Intravitreal Injections and Diabetic Macular Edema: Actual and New Therapeutic Options

Author(s): Nicola Pescosolido, Federica Pranno and Giuseppe Buomprisco

Affiliation: University “Sapienza” of Rome, Faculty of Medicine and Dentistry, Department of Cardiovascular, Respiratory, Nephrologic, Anesthesiologic and Geriatric Sciences, Viale del Policlinico 155, 00161, Rome, Italy.

Abstract

The management of diabetic macular edema (DME) has been revolutionized in recent years. Focal and focal/ grid laser photocoagulation have been the mainstay of treatment for DME for much time. However, nowadays, there is growing evidence that intravitreal VEGF-inhibitors (combined or not with laser photocoagulation) provide better visual outcome in patients with diabetic retinopathy. Hence, anti-VEGF injections are considered the new gold standard to treat diabetic macular edema and eyes with a reduced visual function. Further studies assessing different treatment regimens are underway to define better clinical care pathways.

Keywords: Anti-VEGF, diabetic macular edema, diabetes, neovascularization, rethinopathy, vision loss prevention.

Purchase Online Order Reprints Order Eprints Rights and Permissions

  
  



Article Details

Volume: 9
Issue Number: 6
First Page: 491
Last Page: 498
Page Count: 8
DOI: 10.2174/15733998113096660083
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science